OH-PRVEN-OPTCS/CLDGENERA
12.8.2024 14:01:30 CEST | Business Wire | Press release
Proven Optics, a premier IT Financial Management Solution provider, today announced the acquisition of CloudGenera, a provider of innovative cloud financial optimization solutions, furthering its mission to create the industry’s most complete IT financial management application platform. The CloudGenera acquisition is the first of what the company anticipates will be several acquisitions as Proven Optics scales growth and leverages a majority growth investment from Silversmith Capital Partners and strategic investment from ServiceNow.
CloudGenera offers vendor-agnostic IT analytics that equip organizations with the business cases necessary to optimize their technology expenditures. By leveraging advanced AI and machine learning technologies, CloudGenera automates decisions regarding application migration and modernization and significantly improves the accuracy of cloud cost forecasts, thus enhancing IT decision-making processes.
“The acquisition of CloudGenera marks a significant milestone for Proven Optics as we expand our cloud costing product capabilities,” said William Miller, Founding Partner & Co-CEO of Proven Optics. “Together, Proven Optics and CloudGenera will provide a more complete solution that provides our customers with new IT decision analysis capabilities to generate business cases for cloud migration and optimization.”
Proven Optics was founded in 2020 to provide IT and finance leaders with the necessary analytics and insights to make better business decisions by automating the financial management of complex IT budgets. Delivered on the ServiceNow Platform and available in the ServiceNow Store, the Proven Optics Financial Management Application Suite offers additional value for ServiceNow customers looking to add a financial lens to their decision-making.
The acquisition enhances the value that Proven Optics’ customers derive from their investment in ServiceNow as a strategic platform. By offering critical market intelligence, both Proven Optics and CloudGenera customers will benefit from an integrated solution that improves cloud orchestration and decisions related to budgeting and future forecasting, allowing IT finance and cloud teams to manage the entire process within a single workflow and take full advantage of the power of the ServiceNow platform.
“We are excited to join forces with Bill, Ben, and the entire Proven Optics team,” said Brian Kelly, Founder and CEO of CloudGenera who has joined Proven Optics as Executive Vice President of Product. “Together, we will provide customers with a comprehensive set of tools to enhance IT value and facilitate smarter decision-making across their cloud infrastructure.”
About Proven Optics
Proven Optics is a software company that focuses on one thing: Financial Management. Proven Optics helps clients in both IT and finance organizations implement financial management toolsets on the ServiceNow platform, leveraging 20+ years of practitioner experience and 100+ Commercial and Federal implementations. Our solutions enable modernization of financial management functions, providing IT and Finance leaders with the necessary analytics and insights to make better business decisions. For more information or a demonstration of our products, please visit www.provenoptics.com.
About CloudGenera
Founded in 2012, CloudGenera supplies vendor-agnostic IT analytics that arm organizations with the business cases needed to optimize their technology spend. CloudGenera’s proprietary algorithms automate application migration and modernization decisions. For more information visit https://go.cloudgenera.com/.
Proven Optics is helping you move from simplifying and centralizing your IT financials to supercharging your IT financial decision-making and execution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812664766/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom